Two Sigma Securities’s NovoCure NVCR Stock Holding History

Two Sigma Securities’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,300	Closed	-$199K	–	3414
2023 Q3	$199K	Buy	+12,300	New	+$355K	﹤0.01%	2318

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Two Sigma Securities's NVCR Position: Q1 2026 in Review

Two Sigma Securities sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 20,852 shares — an estimated $270K sold.

Two Sigma Securities first reported a position in NVCR in Q4 2019 and held it in 7 quarters. The position peaked at $1.11M in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Two Sigma Securities reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 20,852 NovoCure shares in Q1 2026, an estimated $270K.
Two Sigma Securities first reported a position in NovoCure in Q4 2019 and held it in 7 quarters.
Two Sigma Securities's NovoCure position peaked at $1.11M in Q1 2022.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.